Clinical Report: Dynamics of Neutrophil EMR3 in Critically Ill Sepsis Patients
Overview
This study evaluates the role of neutrophil EMR3 in early sepsis identification and its dynamics in critically ill patients.
Background
Sepsis remains a leading cause of morbidity and mortality in ICU settings, complicating early diagnosis due to overlapping clinical features with non-infectious inflammatory states. Traditional biomarkers like CRP and PCT are utilized to assess inflammatory burden, but they do not directly indicate the host response's recovery. The study investigates neutrophil EMR3 as a potential marker for early identification and monitoring of sepsis-related host-response dynamics.
Data Highlights
Parameter
Value
AUC for nEMR3 in sepsis discrimination
0.944
nEMR3 sensitivity
93.9%
nEMR3 specificity
83.6%
AUC for ΔDay 7-Day 0 nEMR3
0.882
AUC for Day 7 SOFA
0.877
Key Findings
nEMR3 levels were significantly lower in sepsis patients compared to non-septic ICU patients and healthy controls.
nEMR3 demonstrated superior discrimination for sepsis compared to PCT.
In longitudinal analysis, nEMR3 levels were consistently lower in non-survivors from Day 3 onward.
Changes in nEMR3 from Day 0 to Day 7 provided predictive value for 28-day mortality.
Dynamic changes in nEMR3 were more informative than changes in PCT, CRP, and nCD64 for risk stratification.
Clinical Implications
The findings suggest that nEMR3 may serve as a valuable biomarker for early sepsis identification and monitoring host-response dynamics in critically ill patients. Clinicians should consider integrating nEMR3 measurements alongside traditional biomarkers for a more comprehensive assessment of sepsis.
Conclusion
Neutrophil EMR3 shows promise as a biomarker for early sepsis identification and monitoring recovery dynamics, warranting further investigation in multicenter studies.
